[go: up one dir, main page]

DE69909775D1 - Neue fettanaloge zur behandlung von diabetes - Google Patents

Neue fettanaloge zur behandlung von diabetes

Info

Publication number
DE69909775D1
DE69909775D1 DE69909775T DE69909775T DE69909775D1 DE 69909775 D1 DE69909775 D1 DE 69909775D1 DE 69909775 T DE69909775 T DE 69909775T DE 69909775 T DE69909775 T DE 69909775T DE 69909775 D1 DE69909775 D1 DE 69909775D1
Authority
DE
Germany
Prior art keywords
sub
treating diabetes
new fat
analogs
fat analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69909775T
Other languages
English (en)
Other versions
DE69909775T2 (de
Inventor
Rolf Berge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thia Medica AS
Original Assignee
Thia Medica AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica AS filed Critical Thia Medica AS
Application granted granted Critical
Publication of DE69909775D1 publication Critical patent/DE69909775D1/de
Publication of DE69909775T2 publication Critical patent/DE69909775T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69909775T 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes Expired - Lifetime DE69909775T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
WOPCT/NO98/00143 1998-05-08
PCT/NO1999/000136 WO1999058122A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of diabetes

Publications (2)

Publication Number Publication Date
DE69909775D1 true DE69909775D1 (de) 2003-08-28
DE69909775T2 DE69909775T2 (de) 2004-06-03

Family

ID=19907879

Family Applications (5)

Application Number Title Priority Date Filing Date
DE69910559T Expired - Lifetime DE69910559T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
DE69909775T Expired - Lifetime DE69909775T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
DE69932645T Expired - Lifetime DE69932645D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69932864T Expired - Lifetime DE69932864D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
DE69927805T Expired - Fee Related DE69927805T2 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69910559T Expired - Lifetime DE69910559T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE69932645T Expired - Lifetime DE69932645D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69932864T Expired - Lifetime DE69932864D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
DE69927805T Expired - Fee Related DE69927805T2 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Country Status (17)

Country Link
US (4) US6441036B1 (de)
EP (5) EP1075258B1 (de)
JP (3) JP5057003B2 (de)
KR (3) KR100701502B1 (de)
CN (3) CN1245157C (de)
AT (5) ATE334666T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910296A (de)
CA (3) CA2331408C (de)
DE (5) DE69910559T2 (de)
DK (3) DK1075258T3 (de)
ES (3) ES2204142T3 (de)
NO (3) NO20005461L (de)
NZ (3) NZ508047A (de)
PT (2) PT1075258E (de)
RU (3) RU2219920C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
JP2003514855A (ja) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． カロリー制限の効果を模倣した治療的介入
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
JP4433496B2 (ja) * 2002-05-28 2010-03-17 味の素株式会社 Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用
WO2004000854A1 (en) * 2002-06-20 2003-12-31 Ic Vec Limited Sulfur-containing phospholipid derivatives
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
CN1694704A (zh) 2002-09-06 2005-11-09 詹森药业有限公司 （1h－苯并咪唑－2－基）－（哌嗪基）－甲酮衍生物及其相关化合物作为组胺h4受体拮抗剂用于治疗炎性和过敏性疾病
EP2384750A1 (de) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Verbesserte Glykämiesteuerung für Prädiabetes und/oder Diabetes Typ III mithilfe von Docohexansäure
KR20050071565A (ko) * 2002-10-10 2005-07-07 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
US7705016B2 (en) * 2003-02-13 2010-04-27 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
WO2004082402A1 (en) * 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
EP1718602A4 (de) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd Therapeutische und trägermoleküle
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
WO2005119250A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
RU2394598C2 (ru) * 2004-07-19 2010-07-20 Тиа Медика Ас Композиция, содержащая белковый материал и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
US20070009608A1 (en) * 2004-07-19 2007-01-11 Rolf Berge Composition comprising plant and/or fish oils and compounds comprising non-oxidizable fatty acid entities
RU2272628C1 (ru) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Способ быстрой оптимизации функций кровяных пластинок при метаболическом синдроме
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006083439A2 (en) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Method for lowering serum homocysteine
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
US20090203778A1 (en) 2005-05-04 2009-08-13 Morten Bryhn Fatty acid analogues, i.e. including dha derivatives for uses as a medicament
RU2441061C2 (ru) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
ES2618500T3 (es) * 2006-10-20 2017-06-21 Neurendo Pharma, Llc Método para restaurar el efecto incretina
MX2009004336A (es) * 2006-11-01 2009-05-22 Pronova Biopharma Norge As Lipidos omega-3 alfa-sustituidos que son activadores o moduladores del receptor activado por proliferadores de peroxisoma (ppar).
WO2008132552A2 (en) * 2006-11-01 2008-11-06 Pronova Biopharma Norge As Omega-3 lipid compounds
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
EP2214481B1 (de) 2007-10-15 2019-05-01 United Animal Health, Inc. Verfahren zur erhöhung der leistung von nachkommen
US20100267828A1 (en) * 2007-10-31 2010-10-21 Anne Kristin Holmeide dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
BRPI0910591A2 (pt) * 2008-04-29 2015-09-22 Hoffmann La Roche compostos de butirato de 4-trimetilamônio, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico ou profilático de enfermidades que são moduladas por inibidores de cpt2 e usos dos compostos
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
WO2010033878A2 (en) 2008-09-19 2010-03-25 David Brown Solute concentration measurement device and related methods
DK2427415T3 (da) 2009-05-08 2019-06-11 Basf As Flerumættede fedtsyrer til behandling af sygdomme inden for kardiovaskulære, metaboliske og inflammatoriske sygdomsområder
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US9144575B2 (en) 2010-07-28 2015-09-29 Life Technologies Corporation Anti-viral azide containing compounds
CN107496395A (zh) 2010-11-05 2017-12-22 普罗诺瓦生物医药挪威公司 使用脂质化合物的治疗方法
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP6537980B2 (ja) 2013-02-28 2019-07-03 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
EP2968568A2 (de) 2013-03-11 2016-01-20 Life Science Nutrition AS Natürliche lipide mit nicht oxidierbaren fettsäuren
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
US10034871B2 (en) 2014-11-07 2018-07-31 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
CN115025079A (zh) 2015-04-28 2022-09-09 普罗诺瓦生物医药挪威公司 结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
WO2019083816A1 (en) * 2017-10-23 2019-05-02 Epitracker, Inc. FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME
BR112020011431A2 (pt) 2017-12-06 2020-11-24 Basf As derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica
CA3099482A1 (en) 2018-05-23 2019-11-28 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020180814A1 (en) * 2019-03-04 2020-09-10 Epitracker, Inc. Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain
KR20250043868A (ko) 2023-09-22 2025-03-31 건국대학교 산학협력단 옥시리핀을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
ATE377418T1 (de) * 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
ATE221324T1 (de) * 1996-11-20 2002-08-15 Nutricia Nv Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Also Published As

Publication number Publication date
EP1075259B1 (de) 2003-07-23
RU2223095C2 (ru) 2004-02-10
EP1075258B1 (de) 2003-08-20
CN1302204A (zh) 2001-07-04
ATE334666T1 (de) 2006-08-15
KR100822077B1 (ko) 2008-04-14
CA2331393C (en) 2009-08-11
ATE247464T1 (de) 2003-09-15
EP1075260A2 (de) 2001-02-14
WO1999058121A1 (en) 1999-11-18
KR20010043315A (ko) 2001-05-25
BR9910297A (pt) 2002-01-02
NO20005461L (no) 2001-01-08
EP1285652B1 (de) 2006-08-16
HK1034912A1 (en) 2001-11-09
PT1075258E (pt) 2004-01-30
DE69927805T2 (de) 2006-07-06
KR100701503B1 (ko) 2007-04-02
NZ508046A (en) 2003-08-29
AU761355B2 (en) 2003-06-05
CA2331393A1 (en) 1999-11-18
JP2002514596A (ja) 2002-05-21
KR20010043316A (ko) 2001-05-25
EP1075260B1 (de) 2005-10-19
KR100701502B1 (ko) 2007-04-02
DE69909775T2 (de) 2004-06-03
WO1999058120A1 (en) 1999-11-18
CN1300211A (zh) 2001-06-20
AU5451799A (en) 1999-11-29
DE69932864D1 (de) 2006-09-28
ES2204142T3 (es) 2004-04-16
ES2251218T3 (es) 2006-04-16
JP5057003B2 (ja) 2012-10-24
DE69910559D1 (de) 2003-09-25
WO1999058123A3 (en) 2000-03-09
ATE306916T1 (de) 2005-11-15
CN1244323C (zh) 2006-03-08
JP4465672B2 (ja) 2010-05-19
AU762792B2 (en) 2003-07-03
JP2002514595A (ja) 2002-05-21
US6417232B1 (en) 2002-07-09
CA2331408C (en) 2008-10-21
DK1075260T3 (da) 2006-02-06
WO1999058122A1 (en) 1999-11-18
NO20005462L (no) 2001-01-08
US6441036B1 (en) 2002-08-27
DK1075259T3 (da) 2003-11-03
WO1999058123A2 (en) 1999-11-18
AU4936799A (en) 1999-11-29
JP2002514594A (ja) 2002-05-21
CA2331408A1 (en) 1999-11-18
ATE245416T1 (de) 2003-08-15
RU2219920C2 (ru) 2003-12-27
NZ508045A (en) 2003-08-29
BR9910296A (pt) 2002-01-15
HK1034911A1 (en) 2001-11-09
HK1034909A1 (en) 2001-11-09
CN1300212A (zh) 2001-06-20
US20020198259A1 (en) 2002-12-26
EP1284139B1 (de) 2006-08-02
CA2331395A1 (en) 1999-11-18
US6365628B1 (en) 2002-04-02
DK1075258T3 (da) 2003-12-01
AU7240398A (en) 1999-11-29
AU762790B2 (en) 2003-07-03
CN1245157C (zh) 2006-03-15
ES2207253T3 (es) 2004-05-16
US7026356B2 (en) 2006-04-11
NZ508047A (en) 2003-05-30
DE69910559T2 (de) 2004-06-17
CN1223343C (zh) 2005-10-19
NO333143B1 (no) 2013-03-18
EP1075258A1 (de) 2001-02-14
RU2221558C2 (ru) 2004-01-20
NO20005463D0 (no) 2000-10-30
CA2331395C (en) 2008-10-14
EP1075259A1 (de) 2001-02-14
DE69932645D1 (de) 2006-09-14
NO20005462D0 (no) 2000-10-30
EP1285652A1 (de) 2003-02-26
EP1284139A1 (de) 2003-02-19
NO20005463L (no) 2001-01-08
KR20010043314A (ko) 2001-05-25
PT1075259E (pt) 2003-12-31
NO20005461D0 (no) 2000-10-30
ATE336239T1 (de) 2006-09-15
AU4936699A (en) 1999-11-29
DE69927805D1 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
DE69909775D1 (de) Neue fettanaloge zur behandlung von diabetes
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
DK0554343T3 (da) Liposomer af kurvand stabiliseret i en DNA-gel
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE60134472D1 (de) Oxidationsverfahren zur herstellung des zwischenproduktes 6.alpha.,9.alpha.-difluoro-11.beta.,17.alpone 17.beta.-karbonsäure
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
PL329413A1 (en) Chemical compounds exhibiting properties capable to cause growth hormone release
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
DE59403966D1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
DE69526972D1 (de) Verwendung von Gabapentin in der Behandlung vonAngst - und Panikstörungen
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
FR2396015A1 (fr) Derives de l'acetylene, leur procede de preparation et leur utilisation comme inhibiteurs de monoamine-oxydases pour traiter notamment un etat depressif ou de l'hypertension
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE69926223D1 (de) Verfahren zur herstellung von zwischenprodukten
DE60204014D1 (de) Chlormethylierung von thiophene
DE69109293D1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
ATE163344T1 (de) Zusammensetzungen zur behandlung von geernteter pflanzenmaterial
ES2141384T3 (es) Fabricacion de levobupivacaina y analogos de la misma a partir de l-lisina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition